Medical
-
Aradigm Corporation has partnered with Professors Daniela Traini and Paul Young of the University of Sydney’s Woolcock Institute of Medical Research to develop an aerosol nanoparticle technology to combat fungal and bacterial biofilms. The project… Read more . . .
-
According to an FDA drug shortages report, the US shortage of sumatriptan nasal spray due to a shortage of active ingredient that was first reported in November 2015 should be completely resolved by February 2017.… Read more . . .
-
Raptor Pharmaceutical has presented results from a network meta-analysis of data from clinical trials of inhaled tobramycin, colistimethate sodium, aztreonam and levofloxacin for the treatment of P. aeruginosa lung infections in CF patients. The data,… Read more . . .
-
Patara Pharma has announced Phase 2 results for its PA101 inhaled treatment for refractory chronic cough in patients with idiopathic pulmonary fibrosis (IPF) showing that patients receiving PA101 experienced a statistically significant reduction in cough… Read more . . .
-
According to Vectura, Mundipharma’s Phase 3 trial of the flutiform fluticasone/formoterol MDI failed to demonstrate statistically significant superiority compared to formoterol alone in reducing moderate and severe COPD exacerbations. Mundipharma had planned to seek approval… Read more . . .
-
Paradigm Biopharmaceuticals has announced the completion of a Phase 1 clinical trial of its Rhinosul pentosan polysulfate sodium (PPS) nasal spray for allergic rhinitis. Paradigm said that none of the 18 healthy volunteers involved in… Read more . . .
-
AstraZeneca has announced top-line results from the Phase 3 RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) and CHASE 3 (ChildHood Asthma Safety and Efficacy) studies of the Symbicort budesonide/formoterol fumarate MDI… Read more . . .
-
Windtree Therapeutics has received $1 million from a Phase 2 Small Business Innovation Research Grant (SBIR) worth up to $2.6 million for a Phase 2b trial of its Aerosurf aerosolized KL4 surfactant in premature infants… Read more . . .
-
According to Mast Therapeutics the first patient has been enrolled in a Phase 2 study of its AIR001 sodium nitrite inhalation solution in patients with heart failure with preserved ejection fraction (HFpEF). The multicenter, randomized,… Read more . . .
-
Sunovion has announced results from the Phase 3 GOLDEN-5 48-week safety study of SUN-101 glycopyrrolate inhalation solution in patients with moderate-to-very severe COPD. According to the company, the data show that SUN-101 was well tolerated,… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland